专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009102468A1 6-ARYL-IMIDAZ0[L, 2-A] PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF 审中-公开
标题翻译： 6-ARYL-IMIDAZO [L，2-A]吡嗪衍生物，制备方法及其使用方法
公开(公告)号：WO2009102468A1
公开(公告)日：2009-08-20
申请号：PCT/US2009/000919
申请日：2009-02-12
申请人： CGI PHARMACEUTICALS, INC. , MITCHELL, Scott A. , CURRIE, Kevin S. , BLOMGREN, Peter A. , ARMISTEAD, David M. , RAKER, Joseph
发明人： MITCHELL, Scott A. , CURRIE, Kevin S. , BLOMGREN, Peter A. , ARMISTEAD, David M. , RAKER, Joseph
IPC分类号： C07D487/04 , A61K31/4985 , A61P37/00
CPC分类号： C07D487/04
摘要： Certain chemical entities chosen from compounds represented by Formula I and pharmaceutically acceptable salts and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer (e.g., B -cell lymphoma and leukemia), autoimmune diseases, inflammatory diseases, acute inflammatory reactions, and allergic disorders. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for determining the presence or absence of Syk kinase in a sample. Formula I
摘要翻译：在本文中提供了选自由式I表示的化合物的某些化学实体及其药学上可接受的盐及其混合物。包含至少一种化学实体和一种或多种药学上可接受的载体的药物组合物。公开了治疗患有对抑制Syk活性有反应的某些疾病和病症的患者的方法，所述方法包括向所述患者施用一定量的至少一种有效减少疾病或病症体征或症状的化学实体。这些疾病包括癌症（例如，B细胞淋巴瘤和白血病），自身免疫疾病，炎性疾病，急性炎症反应和过敏性疾病。治疗方法包括给予至少一种化学实体作为单一活性剂或与一种或多种其它治疗剂组合施用至少一种化学实体。还提供了用于确定样品中Syk激酶的存在或不存在的方法。一级方程式

2. 发明申请

WO2007070613A2 RIFAMYCIN ANALOGS AND USES THEREOF 审中-公开
标题翻译： RIFAMYCIN类似物及其用途
公开(公告)号：WO2007070613A2
公开(公告)日：2007-06-21
申请号：PCT/US2006/047648
申请日：2006-12-14
申请人： ACTIVBIOTICS, INCORPORATED , VAN DUZER, John, H. , MICHAELIS, Arthur, F. , GEISS, William, B. , STAFFORD, Douglas, G. , RAKER, Joseph , YU, Xiang, Y. , SIEDLECKI, James, M. , YANG, Yingfei
发明人： VAN DUZER, John, H. , MICHAELIS, Arthur, F. , GEISS, William, B. , STAFFORD, Douglas, G. , RAKER, Joseph , YU, Xiang, Y. , SIEDLECKI, James, M. , YANG, Yingfei
IPC分类号： A61K31/5383 , C07D491/22
CPC分类号： C07D498/18 , C07D519/00
摘要： The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.
摘要翻译：本发明特征为利福霉素类似物和使用这些化合物治疗各种微生物感染的方法。

3. 发明申请

WO2013109732A2 CHITOSAN-DERIVED COMPOSITIONS 审中-公开
标题翻译： CHITOSAN衍生的组合物
公开(公告)号：WO2013109732A2
公开(公告)日：2013-07-25
申请号：PCT/US2013/021903
申请日：2013-01-17
申请人： HODE, Tomas , NORDQUIST, Robert , CHEN, Wei , CARUBELLI, Raoul , ALLERUZZO, Luciano , JENKINS, Peter , WAYNANT, Kristopher , RAKER, Joseph
发明人： HODE, Tomas , NORDQUIST, Robert , CHEN, Wei , CARUBELLI, Raoul , ALLERUZZO, Luciano , JENKINS, Peter , WAYNANT, Kristopher , RAKER, Joseph
IPC分类号： A61K31/722
CPC分类号： C08B37/003 , A61B18/20 , A61K31/722 , A61K39/39 , A61K39/39558 , A61K41/0071 , A61K47/6807 , A61K2039/55583
摘要： The present invention relates generally to therapeutic compositions comprising chitosan- derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.
摘要翻译：本发明一般涉及与用于治疗肿瘤，例如恶性肺，甲状腺和肾脏肿瘤以及其它类型的恶性肿瘤以及其它医学病症的方法组合使用的壳聚糖衍生组合物的治疗组合物。

4. 发明申请

WO2005062882A2 RIFAMYCIN ANALOGS AND USES THEREOF 审中-公开
标题翻译： RIFAMYCIN类似物及其用途
公开(公告)号：WO2005062882A2
公开(公告)日：2005-07-14
申请号：PCT/US2004/043093
申请日：2004-12-21
申请人： ACTIVBIOTICS, INC , VAN DUZER, John, H. , MICHAELIS, Arthur, F. , GEISS, William, B. , STAFFORD, Douglas, G. , RAKER, Joseph , YU, Xiang, Y. , SIEDLECKI, James, M. , YANG, Yingfei
发明人： VAN DUZER, John, H. , MICHAELIS, Arthur, F. , GEISS, William, B. , STAFFORD, Douglas, G. , RAKER, Joseph , YU, Xiang, Y. , SIEDLECKI, James, M. , YANG, Yingfei
IPC分类号： A61K31/498 , A61K31/5383 , A61K31/542 , A61P31/04 , A61P31/10 , C07D491/14 , C07D498/14 , C07D498/18 , C07D513/18 , C07D519/00
CPC分类号： C07D498/18 , C07D513/18 , C07D519/00
摘要： The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3’-hydroxy analogs, 4’-and/or 6’ halo and/or alkoxy analogs, and various 5’ substituents that incorporate a cyclic amine moiety.
摘要翻译：本发明的特征是利福霉素类似物可用作治疗或预防多种微生物感染的治疗剂。在一种形式中，类似物在25位被乙酰化，就像利福霉素一样。在另一种形式中，类似物在25位脱乙酰化。在其他形式中，苯并恶嗪利霉素，苯并噻嗪可的霉素和苯并二氮松霉素类似物在苯环的不同位置衍生化，包括3'-羟基类似物，4'-和/或6'卤素和/或烷氧基类似物，以及各种5'取代基加入环胺部分。

5. 发明公开

EP2252617A1 6-ARYL-IMIDAZ0[L, 2-A]PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF 审中-公开
标题翻译： 6芳基咪唑并[1,2-a]吡嗪，METHOD AND METHOD FOR应用
公开(公告)号：EP2252617A1
公开(公告)日：2010-11-24
申请号：EP09710901.1
申请日：2009-02-12
申请人： CGI Pharmaceuticals, Inc.
发明人： MITCHELL, Scott A. , CURRIE, Kevin S. , BLOMGREN, Peter A. , ARMISTEAD, David M. , RAKER, Joseph
IPC分类号： C07D487/04 , A61K31/4985 , A61P37/00
CPC分类号： C07D487/04
摘要： Certain chemical entities chosen from compounds represented by Formula I and pharmaceutically acceptable salts and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer (e.g., B -cell lymphoma and leukemia), autoimmune diseases, inflammatory diseases, acute inflammatory reactions, and allergic disorders. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for determining the presence or absence of Syk kinase in a sample. Formula I

6. 发明申请

WO2012018909A1 FUSED HETEROCYCLIC COMPOUNDS 审中-公开
标题翻译：熔融杂环化合物
公开(公告)号：WO2012018909A1
公开(公告)日：2012-02-09
申请号：PCT/US2011/046417
申请日：2011-08-03
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , RAKER, Joseph , TANIGUCHI, Takahiko , YOSHIKAWA, Masato , HASUI, Tomoaki , KUNITOMO, Jun
发明人： RAKER, Joseph , TANIGUCHI, Takahiko , YOSHIKAWA, Masato , HASUI, Tomoaki , KUNITOMO, Jun
IPC分类号： C07D471/04 , C07D471/14 , C07D519/00 , A61K31/437 , A61P25/18
CPC分类号： C07D471/04 , C07D471/14 , C07D519/00
摘要： The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1'): wherein, Ring A' represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1' represents (1) wherein, R 1a' represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, -S-, -0-, -CO-, an optionally substituted methylene group, or -NR a' - (R a' represents a hydrogen atom, or an optionally substituted C 1-6 alkyl group), and Ring B 1' represents an optionally further substituted 6- to 10- membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L' and R 1a' may be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, R 1b' represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B 2' represents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D' represents an optionally further substituted 5- or 6- membered ring, R 2' represents a hydrogen atom, or a substituent, X' represents =N- or =CR b' - (R b' represents a hydrogen atom, or a substituent), _ _ _ _ _ represents that R b' and R 2' may form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X' is =CR b' -, or a salt thereof.
摘要翻译：本发明提供了具有PDE 10A抑制作用的化合物，其可用作预防或治疗精神分裂症等的药物。由式（1'）表示的化合物：其中环A'表示任选取代的吡啶环，任选取代的哒嗪环，嘧啶环或吡嗪环，R1'表示（1）其中R1a'表示任选取代的苯基或任选取代的5至10元杂环基，环B2表示键，-S - ， - O-，-CO-，任选取代的亚甲基或-NR a' “表示氢原子或任选取代的C 1-6烷基），并且环B1'表示任选进一步取代的6-至10-元芳族烃环，或任选进一步取代的5至10元芳族杂环，或者可选地，L'和R 1a'可以一起形成任选取代的双环或三环稠合杂环基，或（2），其中，R 1b'表示任选取代的苯基，或任选取代的5-至10- 环B2'代表任选取代的苯环，任选取代的吡啶环，任选取代的嘧啶环，任选取代的吡嗪环或任选取代的哒嗪环，环D'表示任选进一步取代的5-或6-元环，R 2' 表示氢原子或取代基，X'表示= N-或= CRb'-（Rb'表示氢原子或取代基），表示Rb'和R2'可以一起形成与它们各自相邻的碳原子和氮原子，当X'= CRb'-时，任选取代的5-至7-元环，或其盐。

7. 发明申请

WO2005020894A3 RIFAMYCIN ANALOGS AND USES THEREOF 审中-公开
公开(公告)号：WO2005020894A3
公开(公告)日：2005-03-10
申请号：PCT/US2004/026006
申请日：2004-08-11
申请人： ACTIVBIOTICS, INC. , DUZER, John, H., Van , MICHAELIS, Arthur, F. , RAKER, Joseph , STAFFORD, Douglas, G. , GEISS, William, B.
发明人： DUZER, John, H., Van , MICHAELIS, Arthur, F. , RAKER, Joseph , STAFFORD, Douglas, G. , GEISS, William, B.
IPC分类号： C07D498/18 , C07D513/18 , A61K31/538 , A61K31/502 , A61K31/5415 , A61P31/04 , A61P31/12 , A61P33/02
摘要： The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivated at various positions of the benzene ring, including 3’-hydroxy analogs, 4’-and/or 6’halo and/or alkoxy analogs, and various 5’ substituents that incorporate a cyclic amine moiety.

8. 发明申请

WO2003051299A3 SULFHYDRYL RIFAMYCINS AND USES THEREOF 审中-公开
公开(公告)号：WO2003051299A3
公开(公告)日：2003-06-26
申请号：PCT/US2002/039887
申请日：2002-12-12
申请人： ACTIVBIOTICS, INC. , MICHAELIS, Arthur, F. , MAULDING, Hawkins, V. , SAYADA, Chalom , EISENSTEIN, Barry , GEISS, William, B. , RAKER, Joseph
发明人： MICHAELIS, Arthur, F. , MAULDING, Hawkins, V. , SAYADA, Chalom , EISENSTEIN, Barry , GEISS, William, B. , RAKER, Joseph
IPC分类号： A61K31/54
摘要： The invention features sulfhydryl rifamycin compositions, methods of making these compositions, and methods for treating disease using these compositions.

9. 发明申请

WO2020197578A1 SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEM 审中-公开
公开(公告)号：WO2020197578A1
公开(公告)日：2020-10-01
申请号：PCT/US2019/040292
申请日：2019-07-02
申请人： IMMUNOPHOTONICS, INC. , HODE, Tomas , LAM, Siu Kit , RAKER, Joseph , ALLERUZZO, Luciano , NORDQUIST, Robert
发明人： HODE, Tomas , LAM, Siu Kit , RAKER, Joseph , ALLERUZZO, Luciano , NORDQUIST, Robert
IPC分类号： A61K39/39 , A61K39/395
摘要： The present relates generally to a method for stimulating the activation of an antigen presenting cell. The method includes activating antigen presenting cells by contacting the cells with an effective amount of a GC polymer that has a molecular weight of less than 420 kDa, followed by determining whether the antigen presenting cells are activated by measuring the amount of co-stimulatory marker CD40 expressed by the cells. Also, the present relates to an injectable pharmaceutical composition for stimulating the activation of an antigen presenting cell.

10. 发明申请

WO2011163355A1 FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS 审中-公开
标题翻译：熔融杂环化合物作为磷酸二氢钾（PDES）抑制剂
公开(公告)号：WO2011163355A1
公开(公告)日：2011-12-29
申请号：PCT/US2011/041443
申请日：2011-06-22
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , TANIGUCHI, Takahiko , YOSHIKAWA, Masato , MIURA, Kasei , HASUI, Tomoaki , HONDA, Eiji , IMAMURA, Keisuke , KAMATA, Makoto , KAMISAKI, Haruhi , QUINN, John, F. , RAKER, Joseph , CAMARA, Fatoumata , WANG, Yi
发明人： TANIGUCHI, Takahiko , YOSHIKAWA, Masato , MIURA, Kasei , HASUI, Tomoaki , HONDA, Eiji , IMAMURA, Keisuke , KAMATA, Makoto , KAMISAKI, Haruhi , QUINN, John, F. , RAKER, Joseph , CAMARA, Fatoumata , WANG, Yi
IPC分类号： C07D471/04 , C07D473/28 , C07D487/04 , C07D498/04 , A61K31/4355 , A61K31/437 , A61K31/4427 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/52 , A61P25/18
CPC分类号： A61K31/4353 , A61K31/4355 , A61K31/437 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/551 , C07D401/14 , C07D403/04 , C07D403/14 , C07D413/14 , C07D471/04 , C07D471/14 , C07D473/00 , C07D473/28 , C07D487/04 , C07D495/04 , C07D498/04 , C07D498/08 , C07D519/00 , C07F7/10
摘要： The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I) :
摘要翻译：本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗由式（I）表示的精神分裂症等的药剂：

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式